However, several stringent criteria must be met: the drug must demonstrate highly significant effectiveness, meet a substantial unmet medical need, and be developed and submitted for approval in Japan before anywhere else in the world [ 5 ].
← all excerpts
Overview of the Japanese Rapid Introduction Premium as a drug pricing framework to enhance patient access to innovative drugs.
1
—
—